Terms: = Thyroid cancer AND RBM10, GPATC9, 8241, ENSG00000182872, CTD-2522E6_5, GPATCH9, KIAA0122, P98175, MGC1132, DXS8237E, ZRANB5, MGC997 AND Treatment
6488 results:
1. Impact of the thyroid hormone T3 and its nuclear receptor TRα1 on colon cancer stem cell phenotypes and response to chemotherapies.
Giolito MV; Bodoirat S; La Rosa T; Reslinger M; Guardia GDA; Mourtada J; Claret L; Joung A; Galante PAF; Penalva LOF; Plateroti M
Cell Death Dis; 2024 May; 15(5):306. PubMed ID: 38693105
[TBL] [Abstract] [Full Text] [Related]
2. Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells.
Chen Y; Xiao X; Hu G; Liu R; Xue J
J Cancer Res Ther; 2024 Apr; 20(2):570-577. PubMed ID: 38687926
[TBL] [Abstract] [Full Text] [Related]
3. The clinical value of iodine-125 seed implantation in the treatment of iodine-refractory differentiated thyroid carcinoma.
Wan Q; Tan L; Tang X; Wang W; Su Y; Wu Z; Ke M; Chen Z
Front Endocrinol (Lausanne); 2024; 15():1327766. PubMed ID: 38686207
[TBL] [Abstract] [Full Text] [Related]
4. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.
Pasternak B; Wintzell V; Hviid A; Eliasson B; Gudbjörnsdottir S; Jonasson C; Hveem K; Svanström H; Melbye M; Ueda P
BMJ; 2024 Apr; 385():e078225. PubMed ID: 38683947
[TBL] [Abstract] [Full Text] [Related]
5. Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival.
Yang L; Murthy S; Cortellini A; Lim EA; Gonzalez M; Pinato DJ; Abdel-Malek M; Mahmoud S; Martin NM
Front Endocrinol (Lausanne); 2024; 15():1369268. PubMed ID: 38681767
[TBL] [Abstract] [Full Text] [Related]
6. Assessment of thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.
Feier CVI; Vonica RC; Faur AM; Streinu DR; Muntean C
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673931
[TBL] [Abstract] [Full Text] [Related]
7. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study.
Christensen SK; Winther ML; Laursen IJ; Madsen FS; Brink C; Brix TH; Ellebaek E; Svane IM; Hansen FS; Haslund C; Laursen OK; Schmidt H; Larsen ID; Bastholt L; Ruhlmann CH
Support Care Cancer; 2024 Apr; 32(5):281. PubMed ID: 38598052
[TBL] [Abstract] [Full Text] [Related]
8. Development and validation of prediction models for papillary thyroid cancer structural recurrence using machine learning approaches.
Wang H; Zhang C; Li Q; Tian T; Huang R; Qiu J; Tian R
BMC Cancer; 2024 Apr; 24(1):427. PubMed ID: 38589799
[TBL] [Abstract] [Full Text] [Related]
9. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.
Ywata de Carvalho A; Kohler HF; Ywata de Carvalho CCG; Vartanian JG; Kowalski LP
Arch Endocrinol Metab; 2024 Apr; 68():e220506. PubMed ID: 38578436
[TBL] [Abstract] [Full Text] [Related]
10. Impact of neoadjuvant chemotherapy on the safety and long-term outcomes of patients undergoing immediate breast reconstruction after mastectomy.
Nogi H; Ogiya A; Ishitobi M; Yamauchi C; Mori H; Shimo A; Narui K; Nagura N; Seki H; Sasada S; Sakurai T; Shien T;
Breast Cancer; 2024 May; 31(3):507-518. PubMed ID: 38573438
[TBL] [Abstract] [Full Text] [Related]
11. Microwave Ablation versus Surgical Resection for US-detected Multifocal T1N0M0 Papillary thyroid Carcinoma: A 10-Center Study.
Zhao ZL; Wang SR; Dong G; Liu Y; He JF; Shi LL; Guo JQ; Wang ZH; Cong ZB; Liu LH; Yang BB; Qu CP; Niu WQ; Wei Y; Peng LL; Li Y; Lu NC; Wu J; Yu MA
Radiology; 2024 Apr; 311(1):e230459. PubMed ID: 38563669
[TBL] [Abstract] [Full Text] [Related]
12. Radioactive iodine administration is not associated with improved disease-specific survival in classic papillary thyroid carcinoma greater than 4 cm confined to the thyroid.
Lee-Saxton YJ; Palacardo F; Greenberg JA; Egan CE; Marshall TE; Tumati A; Beninato T; Zarnegar R; Fahey TJ; Finnerty BM
Surgery; 2024 Jan; 175(1):215-220. PubMed ID: 38563429
[TBL] [Abstract] [Full Text] [Related]
13. Integrated plasma metabolomic and cytokine analysis reveals a distinct immunometabolic signature in atopic dermatitis.
Ma EZ; Deng J; Parthasarathy V; Lee KK; Pritchard T; Guo S; Zhang C; Kwatra MM; Le A; Kwatra SG
Front Immunol; 2024; 15():1354128. PubMed ID: 38558806
[TBL] [Abstract] [Full Text] [Related]
14. A comparison of the WHO 2004 and WHO 2017 thyroid tumor classifications.
Patel N; Bavikar R; Lad YP; Singh M; Dharwadkar A; Viswanathan V
J Cancer Res Ther; 2024 Jan; 20(1):311-314. PubMed ID: 38554339
[TBL] [Abstract] [Full Text] [Related]
15. The modern landscape of radiotherapy in thyroid malignancies.
Ghosh A; Dagar A; Bharat RP; Sharma A; Sharma DN; Mallick S
J Cancer Res Ther; 2024 Jan; 20(1):1-8. PubMed ID: 38554291
[TBL] [Abstract] [Full Text] [Related]
16. Comparative study between poorly differentiated thyroid cancer and anaplastic thyroid cancer: real-world pathological distribution, death attribution, and prognostic factor estimation.
Zhang K; Wang X; Wei T; Li Z; Zhu J; Chen YW
Front Endocrinol (Lausanne); 2024; 15():1347362. PubMed ID: 38544687
[TBL] [Abstract] [Full Text] [Related]
17. thyroid cancer Survival in the Multiethnic Cohort Study.
Abe JV; Park SY; Haiman CA; Cheng I; Le Marchand L; Hernandez BY; Wilkens LR
Int J Environ Res Public Health; 2024 Mar; 21(3):. PubMed ID: 38541323
[TBL] [Abstract] [Full Text] [Related]
18. Sonographic characteristics of diffuse sclerosing variant of papillary thyroid carcinoma with histopathological correlation: a preliminary study.
Li W; Wang Y; Gao L; Feng R; Lv K; Wu X; Yang X; Cai S; Wang H; Li J
Orphanet J Rare Dis; 2024 Mar; 19(1):136. PubMed ID: 38532506
[TBL] [Abstract] [Full Text] [Related]
19. Stigma, risks, and benefits of medicinal cannabis use among Australians with cancer.
Morris JN; Loyer J; Blunt J
Support Care Cancer; 2024 Mar; 32(4):252. PubMed ID: 38532234
[TBL] [Abstract] [Full Text] [Related]
20. [The association between baseline TPOAb and/or TgAb positivity and thyroid immune-related adverse events in patients with malignancies following treatment with immune checkpoint inhibitors].
Gao Y; Ye T; Wu LG; Xu Y; Wang X; Cheng XQ; Zhang YL; Wang YY; Fan XR; Zhao HT; Liu H; Chai XF; Zhang L; Wang MZ; Li NS; Lian XL
Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(12):963-969. PubMed ID: 38514346
[No Abstract] [Full Text] [Related]
[Next]
